NKARTA INC

RA Capital’s 37,000‑contract option buy at NKARTA hints at strong insider confidence and a promising biotech pipeline, while investors weigh dilution risks and milestone‑driven gains.

Insider buying signals growth potential for Nkarta Inc.: executives are buying options as the company advances its T‑cell therapy pipeline, hinting at future value.